MX2015015519A - Regulador de papalisina. - Google Patents

Regulador de papalisina.

Info

Publication number
MX2015015519A
MX2015015519A MX2015015519A MX2015015519A MX2015015519A MX 2015015519 A MX2015015519 A MX 2015015519A MX 2015015519 A MX2015015519 A MX 2015015519A MX 2015015519 A MX2015015519 A MX 2015015519A MX 2015015519 A MX2015015519 A MX 2015015519A
Authority
MX
Mexico
Prior art keywords
pappalysin
human
mammalian subject
polypeptide
stanniocalcin
Prior art date
Application number
MX2015015519A
Other languages
English (en)
Spanish (es)
Inventor
Claus Oxvig
Jakob Hauge Mikkelsen
Malene Runge Jepsen
Original Assignee
Univ Aarhus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Aarhus filed Critical Univ Aarhus
Publication of MX2015015519A publication Critical patent/MX2015015519A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/38Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489Metalloendopeptidases (3.4.24)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24Metalloendopeptidases (3.4.24)
    • C12Y304/24079Pappalysin-1 (3.4.24.79)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MX2015015519A 2013-05-10 2014-05-12 Regulador de papalisina. MX2015015519A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201370259 2013-05-10
PCT/DK2014/050131 WO2014180485A2 (en) 2013-05-10 2014-05-12 Pappalysin regulator

Publications (1)

Publication Number Publication Date
MX2015015519A true MX2015015519A (es) 2016-07-21

Family

ID=50943008

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015015519A MX2015015519A (es) 2013-05-10 2014-05-12 Regulador de papalisina.

Country Status (9)

Country Link
US (2) US20160151405A1 (https=)
EP (1) EP2994158A2 (https=)
JP (1) JP2016520583A (https=)
CN (1) CN105263510A (https=)
CA (1) CA2911933A1 (https=)
EA (1) EA201591894A1 (https=)
HK (1) HK1215929A1 (https=)
MX (1) MX2015015519A (https=)
WO (1) WO2014180485A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022004054A1 (ja) * 2020-06-30 2022-01-06 国立大学法人東北大学 Stat3のリン酸化抑制剤、自己免疫疾患及びコロナウイルス感染症の予防又は治療剤
WO2022150409A1 (en) * 2021-01-05 2022-07-14 Mayo Foundation For Medical Education And Research Treatments for intraocular pressure related disorders
WO2022270926A1 (ko) * 2021-06-22 2022-12-29 동아대학교 산학협력단 다양한 암의 진단, 전이 또는 예후 예측용 신규한 바이오마커 및 이의 용도
WO2024042220A1 (en) * 2022-08-25 2024-02-29 Aarhus Universitet Modulators of papp-a activity
IL320862A (en) 2022-11-15 2025-07-01 Calico Life Sciences Llc Anti-PAPP-A antibodies and methods of using them
WO2026008015A1 (en) * 2024-07-05 2026-01-08 The University Of Hong Kong Stanniocalcin 2 (stc2) and derivatives as anti-diabetic agents

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994103A (en) * 1995-06-02 1999-11-30 Human Genome Science, Inc. Human stanniocalcin-alpha
CA2387685A1 (en) * 1999-10-27 2001-05-03 Human Genome Sciences, Inc. Stanniocalcin proteins and nucleic acids and methods based thereon
CA2389751A1 (en) 1999-11-01 2001-05-10 Curagen Corporation Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same
US20050009136A1 (en) 2003-02-19 2005-01-13 Dyax Corporation PAPP-A ligands
WO2008101118A2 (en) 2007-02-14 2008-08-21 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services A gene expression signature identifying pro-angiogenic genes in ovarian tumor endothelial cell isolates
US20100292303A1 (en) 2007-07-20 2010-11-18 Birrer Michael J Gene expression profile for predicting ovarian cancer patient survival
KR101720760B1 (ko) 2008-01-25 2017-03-28 오르후스 우니베르시테트 Igfbp-4에 대한 papp-a 활성의 선택적 엑소사이트 억제
WO2010020004A1 (en) * 2008-08-22 2010-02-25 Children's Medical Research Institute Compositions and methods for inhibition of adipogenesis and the treatment of obesity

Also Published As

Publication number Publication date
WO2014180485A3 (en) 2015-03-05
EP2994158A2 (en) 2016-03-16
US11318158B2 (en) 2022-05-03
CN105263510A (zh) 2016-01-20
HK1215929A1 (zh) 2016-09-30
EA201591894A1 (ru) 2016-04-29
WO2014180485A2 (en) 2014-11-13
CA2911933A1 (en) 2014-11-13
US20200261490A1 (en) 2020-08-20
US20160151405A1 (en) 2016-06-02
JP2016520583A (ja) 2016-07-14

Similar Documents

Publication Publication Date Title
MX2015015519A (es) Regulador de papalisina.
PH12019502076A1 (en) Methods for modulating an immune response
PH12013502149A1 (en) Modified acid alpha glucosidase with accelerated processing
PH12017500680A1 (en) Compositions and methods of use for treating metabolic disorders
MX2015008011A (es) Suplementos y sistemas de monitoreo para la dosificacion de los suplementos.
PH12018501903A1 (en) Methods of treating depression using orexin-2 receptor antagonists
TW201613588A (en) Ophthalmic composition
MX2015013727A (es) Composicion para preparacion de uso externo con permeabilidad transdermica mejorada.
AU344488S (en) Wristwatch
SG10201909413SA (en) Method of treating medulloblastoma with an ezh2 inhibitor
SG10201906172XA (en) Regulation of glucose metabolism using anti-cgrp antibodies
MX2019001977A (es) Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados.
PH12014502596A1 (en) Pharmaceutical formulation
PH12018501443A1 (en) Methods of administering hepcidin
IN2014KN02914A (https=)
MX2015012580A (es) El uso de sdf-1 para atenuar la formacion de cicatrices.
NZ631639A (en) Methods and compositions for treating and diagnosing acute myocardial infarction
EP2563350A4 (en) THERAPEUTIC REGIME AND METHOD FOR THE TREATMENT OR IMPROVEMENT OF VIEW DISORDERS ASSOCIATED WITH ENDOGENOUS RETINOID DEFICIENCY
MY186840A (en) Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy
TN2015000315A1 (en) Methods of treating cardiovascular indications
MX2017001737A (es) Vitamina b2 y sus usos.
BR112014029308A2 (pt) um método de melhorar a função hepática
MX2014001271A (es) Tratamiento de diabetes de tipo 2 con fty720.
UA79751U (ru) Способ прогнозирования течения заболевания у больных с первично-локализованной меланомой кожи
UA106603U (uk) Спосіб введення лікувальних засобів